StockData
Mineralys Therapeutics, Inc. logo

Mineralys Therapeutics, Inc. (MLYS) stock

MLYSNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 6/30
$14.48−0.05 (-0.34%)

Close on Nov 17, 2026Market cap $1.28BP/E –Yield –

Mineralys Therapeutics operating cash flow

Operating cash flow is the cash the business generates from its day-to-day operations.

Mineralys Therapeutics's operating cash flow for the twelve months ending Jun 30, 2026 was -$138.79M. For fiscal 2025 it was -$142.42M.

Annual operating cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$142.42M–
FY2024Dec 31, 2024-$166.31M–
FY2023Dec 31, 2023-$81.17M–
FY2022Dec 31, 2022-$29.22M–

Quarterly operating cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$32.56M–
Q1 FY2026Mar 31, 2026-$39.47M–
Q4 FY2025Dec 31, 2025-$37.89M–
Q3 FY2025Sep 30, 2025-$28.87M–
Q2 FY2025Jun 30, 2025-$30.17M–
Q1 FY2025Mar 31, 2025-$45.49M–
Q4 FY2024Dec 31, 2024-$66.84M–
Q3 FY2024Sep 30, 2024-$50.19M–
Q2 FY2024Jun 30, 2024-$30.15M–
Q1 FY2024Mar 31, 2024-$19.14M–
Q4 FY2023Dec 31, 2023-$28.98M–
Q3 FY2023Sep 30, 2023-$19.03M–
Q2 FY2023Jun 30, 2023-$20.39M–
Q1 FY2023Mar 31, 2023-$12.78M–
Q4 FY2022Dec 31, 2022-$10.19M–
Q3 FY2022Sep 30, 2022-$6.99M–
Q2 FY2022Jun 30, 2022-$5.47M–
Q1 FY2022Mar 31, 2022-$6.58M–

More Mineralys Therapeutics figures

See a number that looks wrong?